NEW MUSHROOM PROTEINS AND THESE CODING NUCLEIC ACIDS

Method of screening groups of radioactive molecules and applications thereof

MU-CONOTOXIN PEPTIDES AND USE THEREOF AS A LOCAL ANESTHETIC

The present invention relates to novel mu-conotoxin peptides, biologically active fragments thereof, combinations thereof and /or variants thereof. The invention also relates to their use in pharmaceutical composition for the treatment or prevention of pain, and their use in the preparation of an anesthetic.

Screening libraries of molecules, e.g., to identify drugs and targeting molecules for carrying drugs, by administering a radiolabeled library to animals, and analyzing the distribution of radioactivity

Procédé de criblage, sans amplification, de banques de biomolécules radioactives, produits des banques de biomolécules obtenues ainsi qu'application du procédé à l'identification de molécules capables de se fixer sélectivement à un tissu ou à un organe particulier, utiles au développement de nouveaux composés thérapeutiques, d'agents de contraste pour l'imagerie médicale et au ciblage de médicaments. Le procédé de criblage d'une banque de biomolécules est caractérisé en ce qu'il comprend au moins les étapes suivantes : (1) l'administration, à au moins un animal, de ladite banque de biomolécules, dont chaque biomolécule est préalablement marquée, par un isotope radioactif convenable, (2) le sacrifice d'au moins l'un des animaux et l'analyse de la distribution tissulaire de la radioactivité des biomolécules administrées, à partir de coupes de tissus ou d'organes prélevés, à l'aide d'imageurs convenables, (3) la sélection de coupes de tissus ou d'organes dans le (s) quel (s) un signal de radioactivité ...

Novel fungal proteins and nucleic acids encoding same

Novel fungal proteins and nucleic acids encoding same

MU-CONOTOXIN PEPTIDES AND USE THEREOF AS A LOCAL ANESTHETIC

The present invention relates to novel mu-conotoxin peptides, biologically active fragments thereof, combinations thereof and /or variants thereof. The invention also relates to their use in pharmaceutical composition for the treatment or prevention of pain, and their use in the preparation of an anesthetic.

Screening libraries of molecules, e.g., to identify drugs and targeting molecules for carrying drugs, by administering a radiolabeled library to animals, and analyzing the distribution of radioactivity

Procédé de criblage, sans amplification, de banques de biomolécules radioactives, produits des banques de biomolécules obtenues ainsi qu'application du procédé à l'identification de molécules capables de se fixer sélectivement à un tissu ou à un organe particulier, utiles au développement de nouveaux composés thérapeutiques, d'agents de contraste pour l'imagerie médicale et au ciblage de médicaments. Le procédé de criblage d'une banque de biomolécules est caractérisé en ce qu'il comprend au moins les étapes suivantes : (1) l'administration, à au moins un animal, d'une banque de biomolécules, de formule générale suivante :propyl-3H-NH-Yaa(R,S)Phe(PO2- CH2)(R,S)Leu-Yaa'-NH2, dans laquelle Yaa et Yaa' représentent des positions dans lesquelles figurent les 20 acides aminés naturels et dont chaque biomolécule est préalablement marquée, par un isotope radioactif convenable, (2) le sacrifice d'au moins l'un des animaux et l'analyse de la distribution tissulaire de la radioactivité des biomolécules ...

Antagonisation of anticoagulants

The present invention relates to new peptides of the general formula (I) R<1>-(B<1>)m-(B<2>)n-Tyr-(B<3a>)o(-B<3b>)p-Asnq-Asnr-Tyrs-Leut-B<4>-(Pro)u-Phe-Abu-B<5>-(B<6>)v-R<2>```(I) wherein R<1> represents hydrogen or (C1-C8)-acyl, R<2> represents OH, O-(C1-C8)-alkyl, NH2 or Ala-Asp-Pro-OH, B<1> to B<6> represent, independent of one another, a basic amino acid, such as arginine, homoarginine, lysine, ornithine, 2,4-diaminobutyric acid or 2,3-diaminopropionic acid m,n,o,p,q,r,s,t,u,v represent, independent of one another, zero or 1, and their salts as well as pharmaceutical compositions characterized by containing a myotoxic phospholipase A2 (PLA2) or an other snake venom containing the common peptide sequence KKYKNNYLKPFCKK. The peptides and the pharmaceutical compositions can be used for the antagonisation of heparins, LMWH, pentasaccharide, danaparoid or other related anticoagulants. Reagent kits for in vitro analysis of blood or blood components are also described.

MU-CONOTOXIN PEPTIDES AND USE THEREOF AS A LOCAL ANESTHETIC

The present invention relates to novel mu-conotoxin peptides, biologically active fragments thereof, combinations thereof and /or variants thereof. The invention also relates to their use in pharmaceutical composition for the treatment or prevention of pain, and their use in the preparation of an anesthetic. © KIPO & WIPO 2009 ...

METHOD OF SCREENING GROUPS OF RADIOACTIVE MOLECULES AND APPLICATIONS THEREOF

Mu-conotoxin peptides and use thereof as a local anesthetic

Novel fungal proteins and nucleic acids encoding same

COSMETIC COMPOSITION COMPRISING A MUCONOPEPTIDE

A cosmetic composition containing as an active substance a cosmetically effective amount of at least one mu-conotoxin peptide is provided. In particular, a composition wherein the mu-conotoxin peptide is Arginine, lysine polypeptide (INCI name: pyroglutamyl s-mu-conotoxin CnIIIc amide acetate), CAS Number: 937286-43-6 (renumbered 936616-33-0), Molecular formula C 92 ,H 139 ,N 35 ,O 28 ,S 6 acetate salt (molar mass 2376 g/mol.) is provided. The composition can be used to improve the mechanical properties of the skin, tonicity and/or firmness and/or elasticity of the skin.

Cosmetic composition comprising aconopeptide

The invention concerns a cosmetic composition comprising as an active substance a cosmetically effective amount of at least one mu-conotoxin peptide It further concerns a composition wherein the [mu]-conotoxin peptide is Argninine, lysine polypeptide, CAS Number: 937286-43-6, Molecular formula C92,H139,N35,O28,S6 acetate salt (molar mass 2376 g/mol.). It also concerns the use of a composition according to the invention, to improve the mechanical properties of the skin, tonicity and/or firmness and/or elasticity of the skin.

Mu-conotoxin peptides and use thereof as a local anesthetic

The present invention relates to novel mu-conotoxin peptides, biologically active fragments thereof, combinations thereof and /or variants thereof. The invention also relates to their use in pharmaceutical composition for the treatment or prevention of pain, and their use in the preparation of an anesthetic.

COSMETIC COMPOSITION COMPRISING A MUCONOPEPTIDE

A cosmetic composition including as an active substance a cosmetically effective amount of at least one mu-conotoxin peptide It further concerns a composition wherein the mu-conotoxin peptide is Argninine, lysine polypeptide, CAS Number: 937286-43-6, Molecular formula C92, H139, N35, O28, S6 acetate salt (molar mass 2376 g/mol.). Also, the use of the composition to improve the mechanical properties of the skin, tonicity and/or firmness and/or elasticity of the skin.

Fungal dipeptidyl peptidase IV (DPPIV) enzyme for reagent use

Disclosed herein are fungal nucleic acid sequences that encode novel dipetidyl peptidase IV (DPPIV) polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The aminopeptidase polypeptides, referred to herein as DPPIV proteins of the invention are useful in a variety of medical, research, and commercial applications.

Novel fungal proteins and nucleic acids encoding same

Disclosed herein are fungal nucleic acid sequences that encode novel polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The novel leucine aminopeptidase (LAP) and other amino- and carboxypeptidases polypeptides, referred to herein as EXOX nucleic acids and proteins of the invention are useful in a variety of medical, research, and commercial applications.

Cosmetic composition comprising a muconopeptide

A cosmetic composition containing as an active substance a cosmetically effective amount of at least one mu-conotoxin peptide is provided. In particular, a composition wherein the mu-conotoxin peptide is Arginine, lysine polypeptide (INCI name: pyroglutamyl s-mu-conotoxin CnIIIc amide acetate), CAS Number: 937286-43-6 (renumbered 936616-33-0), Molecular formula C92,H139,N35,O28,S6 acetate salt (molar mass 2376 g/mol.) is provided. The composition can be used to improve the mechanical properties of the skin, tonicity and/or firmness and/or elasticity of the skin.

Mu-Conotoxin Peptides And Use Thereof As A Local Anesthetic

The present invention relates to novel mu-conotoxin peptides, biologically active fragments thereof, combinations thereof and /or variants thereof. The invention also relates to their use in pharmaceutical composition for the treatment or prevention of pain, and their use in the preparation of an anesthetic. 128-. (canceled)29. An isolated and purified nucleic acid sequence comprising Xaa1 is any N-modified amino acid,', 'Xaa2 is glycine,', 'Xaa3 is absent or is any acidic amino acid or any of its amide form,', 'Xaa4 is absent or is glycine,', 'Xaa5 is absent or is proline or hydroxy-proline,', 'Xaa6 is absent or is any basic amino acid,', 'Xaa7 is absent or is glycine,', 'Xaa8 is absent or is any non-aromatic hydroxyl amino acid,', 'Xaa9 is absent or is any non-aromatic hydroxyl amino acid,', 'Xaa10 is absent or is any basic amino acid,', 'Xaa11 is absent or is any aromatic amino acid,', 'Xaa12 is absent or is any basic amino acid,', 'Xaa13 is absent or is any acidic amino acid or any of its amide form,', 'Xaa14 is absent or is any basic amino acid, or any sulfur-containing amino acid,', 'Xaa15 is absent or is any hydrophobic or apolar amino acid, or any non-aromatic hydroxyl amino acid,, 'i) a nucleotide sequence encoding a tnu-conotoxin peptide consisting of the amino acid sequence: Xaa1-Xaa2-Cys-Cys-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7-Cys-Xaa8-Xaa9-Xaa10-Xaa11-Cys-Xaa12-Xaa13-Xaa14-Xaa15-Xaa16-Cys-Cys-Xaa17 [SEQ ID NO:1], wherein'}Xaa16 is absent or is any basic amino acid,Xaa17 is absent or is any apolar amino acid, or an amide group,ii) a nucleic acid sequence complementary to i),iii) a degenerated nucleic acid sequence of i) or ii),iv) a nucleic acid sequence capable of hybridizing under stringent conditions to or iii),v) a nucleic acid sequence encoding a truncation or an analog of the mu-conotoxin peptide,vi) and/or a fragment of i), ii), iii), or v) encoding a biologically active fragment of the mu-conotoxin peptide.30. A vector comprising the isolated and purified ...

Cosmetic composition comprising a muconopeptide

A cosmetic composition including as an active substance a cosmetically effective amount of at least one mu-conotoxin peptide It further concerns a composition wherein the mu-conotoxin peptide is Argninine, lysine polypeptide, CAS Number: 937286-43-6, Molecular formula C 92 ,H 139 ,N 35 ,O 28 ,S 6 acetate salt (molar mass 2376 g/mol.). Also, the use of the composition to improve the mechanical properties of the skin, tonicity and/or firmness and/or elasticity of the skin.

Fungal proteins and nucleic acids encoding same

Disclosed herein are fungal nucleic acid sequences that encode novel polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The novel leucine aminopeptidase (LAP) and other amino- and carboxypeptidases polypeptides, referred to herein as EXOX nucleic acids and proteins of the invention are useful in a variety of medical, research, and commercial applications.

Fungal proteins and nucleic acids encoding same

Disclosed herein are fungal nucleic acid sequences that encode novel polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The novel leucine aminopeptidase (LAP) and other amino- and carboxypeptidases polypeptides, referred to herein as EXOX nucleic acids and proteins of the invention are useful in a variety of medical, research, and commercial applications.

Method of screening groups of radioactive molecules and applications thereof

The invention relates to an amplification-free method of screening groups of radioactive molecules, comprising at least the following steps: (1) the group of molecules is administered to at least one animal; (2) at least one of the animals is slaughtered and the tissue distribution of the radioactivity of the molecules administered is analyzed in vivo; (3) sections of tissue or organs in which a radioactivity signal is detected are selected; (4) radioactive fractions from the sections of tissue or organs are isolated using suitable techniques such as chromatography and/or extraction techniques; and (5) the molecule(s) from the radioactive fractions obtained in step 4 are characterized using suitable analysis techniques such as chromatography and/or mass spectrometry.

Novel fungal proteins and nucleic acids encoding same

Disclosed herein are fungal nucleic acid sequences that encode novel polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The novel leucine aminopeptidase (LAP) and other amino- and carboxypeptidases polypeptides, referred to herein as EXOX nucleic acids and proteins of the invention are useful in a variety of medical, research, and commercial applications.

Mu-Conotoxin Peptides and Use Thereof as a Local Anesthetic

In one embodiment, the present invention relates to novel mu-conotoxin peptides, biologically active fragments thereof, combinations thereof and/or variants thereof. An embodiment of the invention also relates to their use in pharmaceutical composition for the treatment or prevention of pain, and their use in the preparation of an anesthetic.

MU-CONOTOXIN PEPTIDES AND USE THEREOF AS A LOCAL ANESTHETIC

The present invention relates to novel mu-conotoxin peptides, biologically active fragments thereof, combinations thereof and/or variants thereof. The invention also relates to their use in pharmaceutical composition for the treatment or prevention of pain, and their use in the preparation of an anesthetic. 2. The mu-conotoxin peptide of claim 1 , wherein at least one amino acid consisting of amino acids Xaa3 claim 1 , Xaa4 claim 1 , Xaa5 claim 1 , Xaa6 and Xaa7 is absent.3. The mu-conotoxin peptide of claim 1 , wherein at least one amino acid consisting of amino acids Xaa8 claim 1 , Xaa9 claim 1 , Xaa10 and Xaa11 is absent.4. The mu-conotoxin peptide of claim 1 , wherein at least one amino acid consisting of amino acids Xaa12 claim 1 , Xaa13 claim 1 , Xaa14 claim 1 , Xaa15 and Xaa16 is absent.5. The mu-conotoxin peptide of claim 1 , whereinthe N-modification of amino-acid Xaa1 is selected from the group consisting of acetylation, formylation, myristoylation and amidation;Xaa3 and Xaa13 are independently selected from the group consisting of aspartic acid (Asp), asparagine (Asn), glutamic acid (Glu), glutamine (Gln) and pyroglutamic acid (pGlu or Z);Xaa6, Xaa10, Xaa12 and Xaa16 are independently selected from the group consisting of arginine (Arg), lysine (Lys) and histidine (His);Xaa8 and Xaa9 are independently selected from the group consisting of serine (Ser) and threonine (Thr);Xaa11 is selected from the group consisting of phenylalanine (Phe), tyrosine (Tyr), and tryptophan (Trp);Xaa14 is selected from the group consisting of arginine (Arg), lysine (Lys), histidine (His), cysteine (Cys) and methionine (Met);Xaa15 is selected from the group consisting of glycine (Gly), alanine (Ala), valine (Val), leucine (Leu), isoleucine (Ile), serine (Ser), threonine (Thr), methionine (Met), cysteine (Cys) and proline (Pro);Xaa17 is selected from the group consisting of glycine (Gly), alanine (Ala), valine (Val), leucine (Leu), isoleucine (Ile), threonine (Thr), methionine ( ...

COSMETIC COMPOSITION COMPRISING A MUCONOPEPTIDE

A cosmetic composition including as an active substance a cosmetically effective amount of at least one mu-conotoxin peptide It further concerns a composition wherein the mu-conotoxin peptide is Argninine, lysine polypeptide, CAS Number: 937286-43-6, Molecular formula C, H, N, O, Sacetate salt (molar mass 2376 g/mol.). Also, the use of the composition to improve the mechanical properties of the skin, tonicity and/or firmness and/or elasticity of the skin. 1. A cosmetic composition comprising as an active substance a cosmetically effective amount of at least one mu-conotoxin peptide comprising the amino acid sequence:Xaa1-Xaa2-Cys-Cys-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7-Cys-Xaa8-Xaa9-Xaa10-Xaa11-Cys-Xaa12-Xaa13-Xaa14-Xaa15-Xaa16-Cys-Cys-Xaa17 [SEQ ID No 1]a biologically active fragment thereof, a salt thereof, a combination thereof and/or variants thereof, and wherein Xaa1 is any N-modified amino acid,Xaa2 is glycine,Xaa3 is any acidic amino acid or any of its amide form,Xaa4 is glycine,Xaa5 is proline or hydroxy-proline,Xaa6 is any basic amino acid,Xaa7 is glycine,Xaa8 is any non-aromatic hydroxyl amino acid,Xaa9 is any non-aromatic hydroxyl amino acid,Xaa10 is any basic amino acid,Xaa11 is any aromatic amino acid,Xaa12 is any basic amino acid,Xaa13 is any acidic amino acid or any of its amide form,Xaa14 is any basic amino acid, or any sulfur-containing amino acid,Xaa15 is any hydrophobic or apolar amino acid, or any non-aromatic hydroxyl amino acid,Xaa16 is any basic amino acid,Xaa17 is absent or is any apolar amino acid, or an amide group, optionally in combination with cosmetic acceptable carriers, diluents and/or adjuvants.2. The composition of claim 1 , wherein the mu-conotoxin peptide does not comprise at least one amino acid consisting of amino acids Xaa3 claim 1 , Xaa4 claim 1 , Xaa5 claim 1 , Xaa6 and Xaa7 claim 1 , or any combination thereof.3. The composition of claim 1 , wherein the mu-conotoxin peptide does not comprise at least one amino acid consisting of amino ...

Mu-Conotoxin Peptides And Use Thereof As A Local Anesthetic

The present invention relates to novel mu-conotoxin peptides, biologically active fragments thereof, combinations thereof and/or variants thereof. The invention also relates to their use in pharmaceutical composition for the treatment or prevention of pain, and their use in the preparation of an anesthetic. 128-. (canceled)29. An isolated and purified nucleic acid sequence comprising Xaa1 is any N-modified amino acid,', 'Xaa2 is glycine,', 'Xaa3 is absent or is any acidic amino acid or any of its amide form,', 'Xaa4 is absent or is glycine,', 'Xaa5 is absent or is proline or hydroxy-proline,', 'Xaa6 is absent or is any basic amino acid,', 'Xaa7 is absent or is glycine,', 'Xaa8 is absent or is any non-aromatic hydroxyl amino acid,', 'Xaa9 is absent or is any non-aromatic hydroxyl amino acid,', 'Xaa10 is absent or is any basic amino acid,', 'Xaa11 is absent or is any aromatic amino acid,', 'Xaa12 is absent or is any basic amino acid,', 'Xaa13 is absent or is any acidic amino acid or any of its amide form,', 'Xaa14 is absent or is any basic amino acid, or any sulfur-containing amino acid,', 'Xaa15 is absent or is any hydrophobic or apolar amino acid, or any non-aromatic hydroxyl amino acid,, 'i) a nucleotide sequence encoding a mu-conotoxin peptide consisting of the amino acid sequence: Xaa1-Xaa2-Cys-Cys-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7-Cys-Xaa8-Xaa9-Xaa10-Xaa11-Cys-Xaa12-Xaa13-Xaa14-Xaa15-Xaa16-Cys-Cys-Xaa17 [SEQ ID NO:1], wherein'}Xaa16 is absent or is any basic amino acid,Xaa17 is absent or is any apolar amino acid, or an amide group,ii) a nucleic acid sequence complementary to i),iii) a degenerated nucleic acid sequence of i) or ii),iv) a nucleic acid sequence capable of hybridizing under stringent conditions to or iii),v) a nucleic acid sequence encoding a truncation or an analog of the mu-conotoxin peptide,vi) and/or a fragment of i), ii), iii), or v) encoding a biologically active fragment of the mu-conotoxin peptide.30. A vector comprising the isolated and purified ...

METHOD FOR SCREENING BIOMOLECULE BANKS AND APPLICATIONS THEREOF

Sample transfer system

The present invention relates to a sample transfer system that is suitable for electrophysiological measurements on voltage-clamped cells, patches of membrane, tissue, embryo, small living organisms or inorganic samples, that can be exposed to different test compound solutions, wherein said test compound solutions can be retrieved after the measurements. The invention also provides for a method to transfer a cell or biological sample, e.g. from one aqueous solution bath to another, while protecting it from being exposed to mechanical forces at the air-liquid interface.

Mu-conotoxin peptides and use thereof as a local anesthetic

The present invention relates to novel mu-conotoxin peptides, biologically active fragments thereof, combinations thereof and/or variants thereof. The invention also relates to their use in pharmaceutical composition for the treatment or prevention of pain, and their use in the preparation of an anesthetic.

Novel fungal proteins and nucleic acids encoding same

Disclosed herein are fungal nucleic acid sequences that encode novel polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The novel leucine aminopeptidase (LAP) and other amino- and carboxypeptidases polypeptides, referred to herein as EXOX nucleic acids and proteins of the invention are useful in a variety of medical, research, and commercial applications.

Method of screening groups of radioactive molecules and applications thereof

The invention relates to an amplification-free method of screening groups of radioactive molecules, the products from the molecule groups obtained and the application thereof in order to identify molecules that are capable of binding selectively to a tissue or a particular organ. The inventive method can be used for the development of novel therapeutic compounds and contrast agents for medical imaging and for the screening of medicaments. Said method of screening a group of molecules is characterised in that it comprises at least the following steps: (1) the group of molecules is administered to at least one animal, each molecule being marked first by a suitable radioactive isotope; (2) at least one of the animals is slaughtered and the tissue distribution of the radioactivity of the molecules administered is analysed from sections of tissue or organs taken using suitable imaging devices; (3) sections of tissue or organs in which a radioactivity signal is detected are selected; (4) radioactive fractions from the aforementioned sections of tissue or organs selected during step 3 are isolated using suitable techniques such as chromatography and/or extraction techniques; and (5) the molecule(s) from the radioactive fractions obtained in step 4 are characterised using suitable analysis techniques such as chromatography and/or mass spectrometry. According to one variation of the method, in step 2, where possible, the tissue distribution of the radioactivity of the molecules administered is analysed in vivo using suitable imaging devices from a biological sample which is pre-extracted and selected from the group containing cells and sections of tissue or organs. As a result, said variation does not require the animal to be slaughtered.

METHOD FOR SCREENING BIOMOLECULE BANKS AND APPLICATIONS THEREOF

Novel fungal proteins and nucleic acids encoding same

Disclosed herein are fungal nucleic acid sequences that encode novel polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The novel leucine aminopeptidase (LAP) and other amino- and carboxypeptidases polypeptides, referred to herein as EXOX nucleic acids and proteins of the invention are useful in a variety of medical, research, and commercial applications.

Neue pilzproteine und diese codierende nukleinsäuren

Peptides for antagonisation of anticoagulants and uses thereof

The present invention relates to peptides and compositions, in particular pharmaceutical compositions, in particular those of the general formula (I) R1-(B1)m-(B2)n-Tyr-(B3a)o-(B3b)p-Asnq-Asnr-Tyrs-Leut-B4-(Pro)u-Phe-Abu-B5-(B6)v-R2 (I) wherein R1 represents hydrogen or (C1-C8)-acyl, R2 represents OH, O-(C1-C8)-alkyl, NH2 or Ala-Asp-Pro-OH, B1 to B6 represent, independent of one another, a basic amino acid, such as arginine, homoarginine, lysine, ornithine, 2,4-diaminobutyric acid or 2,3-diaminopropionic acid, m,n,o,p,q,r,s,t,u,v represent, independent of one another, zero or 1, and their salts as well as pharmaceutical compositions characterized by containing a myotoxic phospholipase A2 (PLA2) or an other snake venom containing the common peptide sequence KKYKNNYLKPFCKK. The peptides and the pharmaceutical compositions can be used for the antagonisation of heparins and heparin-based anticoagulants. Reagent kits for in vitro analysis of blood or blood components are also described.

Cosmetic composition comprising a muconopeptide

Cosmetic composition comprising a muconopeptide

The invention concerns a cosmetic composition comprising as an active substance a cosmetically effective amount of at least one mu-conotoxin peptide It further concerns a composition wherein the mu-conotoxin peptide is Argninine, lysine polypeptide, CAS Number: 937286-43-6, Molecular formula C92,H139,N35,028,S6 acetate salt (molar mass 2376 g/mol.). It also concerns the use of a composition according to the invention, to improve the mechanical properties of the skin, tonicity and/or firmness and/or elasticity of the skin.